[{"data":1,"prerenderedAt":37},["ShallowReactive",2],{"news-2025-09-orion-collaboration":3},{"id":4,"title":5,"body":6,"date":26,"description":12,"extension":27,"kind":28,"link":29,"meta":30,"navigation":31,"path":32,"seo":33,"stem":34,"summary":35,"__hash__":36},"news\u002Fnews\u002F2025-09-orion-collaboration.md","Abilita announces multi-target collaboration with Orion",{"type":7,"value":8,"toc":22},"minimark",[9,13,16],[10,11,12],"p",{},"Abilita Therapeutics today announced a research collaboration with Orion\nCorporation focused on discovering antibody therapeutics against a series of\nmulti-span GPCR targets. Under the agreement, Abilita applies its EMP™\ndirected-evolution platform to stabilise targets selected by Orion, enabling\ndownstream antibody discovery campaigns.",[10,14,15],{},"The collaboration extends Abilita's track record of partnerships with global\npharma — joining ongoing relationships with Lilly, Amgen, Bristol Myers\nSquibb, GSK, and Regeneron.",[17,18,19],"content-gate",{},[10,20,21],{},"Deal-value language withheld pending client confirmation of public-facing\nfinancial disclosure.",{"title":23,"searchDepth":24,"depth":24,"links":25},"",2,[],"2025-09-04","md","press",null,{},true,"\u002Fnews\u002F2025-09-orion-collaboration",{"title":5,"description":12},"news\u002F2025-09-orion-collaboration","Multi-year discovery collaboration applies Abilita's EMP™ platform to a series of GPCR targets selected by Orion.","64BAY5qDprO9skvoXA4dZJg51RxdlGlgbi3gamZj3Yw",1779487983620]